PP
ALDX icon

Paloma Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Paloma Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,546
Closed -$62.2K – 298
2024
Q3 		$62.2K Buy
+11,546
New +$55K ﹤0.01% 1065
2020
Q3 		– Sell
-122,947
Closed -$512K – 2041
2020
Q2 		$512K Buy
+122,947
New +$449K 0.01% 1210

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Paloma Partners's ALDX Position: Q4 2024 in Review

Paloma Partners sold out of Aldeyra Therapeutics (ALDX) in Q4 2024, closing a stake of 11,546 shares — an estimated $62.2K sold.

Paloma Partners first reported a position in ALDX in Q2 2020 and held it in 2 quarters. The position peaked at $512K in Q2 2020. 118 funds tracked by Wall St. Rank hold ALDX as of Q4 2024.

  • Paloma Partners reported no remaining Aldeyra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 11,546 Aldeyra Therapeutics shares in Q4 2024, an estimated $62.2K.
  • Paloma Partners first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 2 quarters.
  • Paloma Partners's Aldeyra Therapeutics position peaked at $512K in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.